Cancer and Metastasis Reviews最新文献_第4页

Epidemiology of nasopharyngeal carcinoma: current insights and future outlook. 鼻咽癌流行病学：当前见解与未来展望。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-09-01 Epub Date: 2024-03-02 DOI: 10.1007/s10555-024-10176-9

Zhi Yi Su, Pui Yan Siak, Yu Yu Lwin, Shiau-Chuen Cheah

{"title":"Epidemiology of nasopharyngeal carcinoma: current insights and future outlook.","authors":"Zhi Yi Su, Pui Yan Siak, Yu Yu Lwin, Shiau-Chuen Cheah","doi":"10.1007/s10555-024-10176-9","DOIUrl":"10.1007/s10555-024-10176-9","url":null,"abstract":"Nasopharyngeal carcinoma (NPC) is characterised by its remarkable geographical and ethnic distribution. The interplay between genetic susceptibility, environmental exposures, and Epstein-Barr virus (EBV) infections is indicated in the development of NPC. Exposure to tobacco smoking, dietary factors, and inhalants has been associated with the risk of NPC. Genetic association studies have revealed NPC-associated susceptibility loci, including genes involved in immune responses, xenobiotic metabolism, genome maintenance, and cell cycle regulation. EBV exposure timing and strain variation might play a role in its carcinogenicity, although further investigations are required. Other factors including medical history and oral hygiene have been implicated in NPC. Prevention strategies, including primary prevention and secondary prevention through early detection, are vital in reducing mortality and morbidity of NPC. The current review discusses the global and regional distribution of NPC incidences, the risk factors associated with NPC, and the public health implications of these insights. Future investigations should consider international, large-scale prospective studies to elucidate the mechanisms underlying NPC pathogenesis and develop individualized interventions for NPC.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":null,"pages":null},"PeriodicalIF":7.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140012211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

OX40/OX40 ligand and its role in precision immune oncology. OX40/OX40 配体及其在精准免疫肿瘤学中的作用。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-09-01 Epub Date: 2024-03-25 DOI: 10.1007/s10555-024-10184-9

Bicky Thapa, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary K Nesline, Rebecca A Previs, Jeffery M Conroy, Paul DePietro, Sarabjot Pabla, Razelle Kurzrock

{"title":"OX40/OX40 ligand and its role in precision immune oncology.","authors":"Bicky Thapa, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary K Nesline, Rebecca A Previs, Jeffery M Conroy, Paul DePietro, Sarabjot Pabla, Razelle Kurzrock","doi":"10.1007/s10555-024-10184-9","DOIUrl":"10.1007/s10555-024-10184-9","url":null,"abstract":"Immune checkpoint inhibitors have changed the treatment landscape for various malignancies; however, their benefit is limited to a subset of patients. The immune machinery includes both mediators of suppression/immune evasion, such as PD-1, PD-L1, CTLA-4, and LAG-3, all of which can be inhibited by specific antibodies, and immune-stimulatory molecules, such as T-cell co-stimulatory receptors that belong to the tumor necrosis factor receptor superfamily (TNFRSF), including OX40 receptor (CD134; TNFRSF4), 4-1BB (CD137; TNFRSF9), and glucocorticoid-induced TNFR-related (GITR) protein (CD357; TNFRSF18). In particular, OX40 and its binding ligand OX40L (CD134L; TNFSF4; CD252) are critical for immunoregulation. When OX40 on activated T cells binds OX40L on antigen-presenting cells, T-cell activation and immune stimulation are initiated via enhanced T-cell survival, proliferation and cytotoxicity, memory T-cell formation, and abrogation of regulatory T cell (Treg) immunosuppressive functions. OX40 agonists are in clinical trials both as monotherapy and in combination with other immunotherapy agents, in particular specific checkpoint inhibitors, for cancer treatment. To date, however, only a minority of patients respond. Transcriptomic profiling reveals that OX40 and OX40L expression vary between and within tumor types, and that only ~ 17% of cancer patients have high OX40 and low OX40L, one of the expression patterns that might be theoretically amenable to OX40 agonist enhancement. Taken together, the data suggest that the OX40/OX40L machinery is a critical part of the immune stimulatory system and that understanding endogenous expression patterns of these molecules and co-existing checkpoints merits further investigation in the context of a precision immunotherapy strategy for cancer therapy.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":null,"pages":null},"PeriodicalIF":7.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma. TECENTRIQ®和OPDIVO®的综合评估：分析三阴性乳腺癌和肝细胞癌的免疫疗法适应症。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-09-01 Epub Date: 2024-02-27 DOI: 10.1007/s10555-024-10174-x

Ghazaal Roozitalab, Behnaz Abedi, Saber Imani, Reyhaneh Farghadani, Parham Jabbarzadeh Kaboli

{"title":"Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma.","authors":"Ghazaal Roozitalab, Behnaz Abedi, Saber Imani, Reyhaneh Farghadani, Parham Jabbarzadeh Kaboli","doi":"10.1007/s10555-024-10174-x","DOIUrl":"10.1007/s10555-024-10174-x","url":null,"abstract":"Atezolizumab (TECENTRIQ®) and nivolumab (OPDIVO®) are both immunotherapeutic indications targeting programmed cell death 1 ligand 1 (PD-L1) and programmed cell death 1 (PD-1), respectively. These inhibitors hold promise as therapies for triple-negative breast cancer (TNBC) and hepatocellular carcinoma (HCC) and have demonstrated encouraging results in reducing the progression and spread of tumors. However, due to their adverse effects and low response rates, the US Food and Drug Administration (FDA) has withdrawn the approval of atezolizumab in TNBC and nivolumab in HCC treatment. The withdrawals of atezolizumab and nivolumab have raised concerns regarding their effectiveness and the ability to predict treatment responses. Therefore, the current study aims to investigate the immunotherapy withdrawal of PD-1/PD-L1 inhibitors, specifically atezolizumab for TNBC and nivolumab for HCC. This study will examine both the structural and clinical aspects. This review provides detailed insights into the structure of the PD-1 receptor and its ligands, the interactions between PD-1 and PD-L1, and their interactions with the withdrawn antibodies (atezolizumab and nivolumab) as well as PD-1 and PD-L1 modifications. In addition, this review further assesses these antibodies in the context of TNBC and HCC. It seeks to elucidate the factors that contribute to diverse responses to PD-1/PD-L1 therapy in different types of cancer and propose approaches for predicting responses, mitigating the potential risks linked to therapy withdrawals, and optimizing patient outcomes. By better understanding the mechanisms underlying responses to PD-1/PD-L1 therapy and developing strategies to predict these responses, it is possible to create more efficient treatments for TNBC and HCC.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":null,"pages":null},"PeriodicalIF":7.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TFCP2 as a therapeutic nexus: unveiling molecular signatures in cancer. 作为治疗纽带的 TFCP2：揭示癌症的分子特征。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-09-01 Epub Date: 2024-03-07 DOI: 10.1007/s10555-024-10175-w

Neha Kaushik, Apurva Jaiswal, Pradeep Bhartiya, Eun Ha Choi, Nagendra Kumar Kaushik

{"title":"TFCP2 as a therapeutic nexus: unveiling molecular signatures in cancer.","authors":"Neha Kaushik, Apurva Jaiswal, Pradeep Bhartiya, Eun Ha Choi, Nagendra Kumar Kaushik","doi":"10.1007/s10555-024-10175-w","DOIUrl":"10.1007/s10555-024-10175-w","url":null,"abstract":"Tumor suppressor genes and proto-oncogenes comprise most of the complex genomic landscape associated with cancer, with a minimal number of genes exhibiting dual-context-dependent functions. The transcription factor cellular promoter 2 (TFCP2), a pivotal transcription factor encoded by the alpha globin transcription factor CP2 gene, is a constituent of the TFCP2/grainyhead family of transcription factors. While grainyhead members have been extensively studied for their crucial roles in developmental processes, embryogenesis, and multiple cancers, the TFCP2 subfamily has been relatively less explored. The molecular mechanisms underlying TFCP2's involvement in carcinogenesis are still unclear even though it is a desirable target for cancer treatment and a therapeutic marker. This comprehensive literature review summarizes the molecular functions of TFCP2, emphasizing its involvement in cancer pathophysiology, particularly in the epithelial-mesenchymal transition and metastasis. It highlights TFCP2's critical function as a regulatory target and explores its potential as a prognostic marker for survival and inflammation in carcinomas. Its ambiguous association with carcinomas underlines the urgent need for an in-depth understanding to facilitate the development of more efficacious targeted therapeutic modality and diagnostic tools. This study aims to elucidate the multifaceted effects of TFCP2 regulation, through a comprehensive integration of the existing knowledge in cancer therapeutics. Furthermore, the clinical relevance and the inherent challenges encountered in investigating its intricate role in cancer pathogenesis have been discussed in this review.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":null,"pages":null},"PeriodicalIF":7.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140048853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Deciphering cellular and molecular mechanism of MUC13 mucin involved in cancer cell plasticity and drug resistance. 破译 MUC13 粘蛋白参与癌细胞可塑性和耐药性的细胞和分子机制。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-09-01 Epub Date: 2024-03-18 DOI: 10.1007/s10555-024-10177-8

Shabnam Malik, Mohammed Sikander, Mohd Wahid, Anupam Dhasmana, Maryam Sarwat, Sheema Khan, Everardo Cobos, Murali M Yallapu, Meena Jaggi, Subhash C Chauhan

{"title":"Deciphering cellular and molecular mechanism of MUC13 mucin involved in cancer cell plasticity and drug resistance.","authors":"Shabnam Malik, Mohammed Sikander, Mohd Wahid, Anupam Dhasmana, Maryam Sarwat, Sheema Khan, Everardo Cobos, Murali M Yallapu, Meena Jaggi, Subhash C Chauhan","doi":"10.1007/s10555-024-10177-8","DOIUrl":"10.1007/s10555-024-10177-8","url":null,"abstract":"There has been a surge of interest in recent years in understanding the intricate mechanisms underlying cancer progression and treatment resistance. One molecule that has recently emerged in these mechanisms is MUC13 mucin, a transmembrane glycoprotein. Researchers have begun to unravel the molecular complexity of MUC13 and its impact on cancer biology. Studies have shown that MUC13 overexpression can disrupt normal cellular polarity, leading to the acquisition of malignant traits. Furthermore, MUC13 has been associated with increased cancer plasticity, allowing cells to undergo epithelial-mesenchymal transition (EMT) and metastasize. Notably, MUC13 has also been implicated in the development of chemoresistance, rendering cancer cells less responsive to traditional treatment options. Understanding the precise role of MUC13 in cellular plasticity, and chemoresistance could pave the way for the development of targeted therapies to combat cancer progression and enhance treatment efficacy.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":null,"pages":null},"PeriodicalIF":7.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140142784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumor-associated fibrosis: a unique mechanism promoting ovarian cancer metastasis and peritoneal dissemination. 肿瘤相关纤维化：促进卵巢癌转移和腹膜扩散的独特机制

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-09-01 Epub Date: 2024-03-28 DOI: 10.1007/s10555-024-10169-8

Hiroki Fujimoto, Masato Yoshihara, Raymond Rodgers, Shohei Iyoshi, Kazumasa Mogi, Emiri Miyamoto, Sae Hayakawa, Maia Hayashi, Satoshi Nomura, Kazuhisa Kitami, Kaname Uno, Mai Sugiyama, Yoshihiro Koya, Yoshihiko Yamakita, Akihiro Nawa, Atsushi Enomoto, Carmela Ricciardelli, Hiroaki Kajiyama

{"title":"Tumor-associated fibrosis: a unique mechanism promoting ovarian cancer metastasis and peritoneal dissemination.","authors":"Hiroki Fujimoto, Masato Yoshihara, Raymond Rodgers, Shohei Iyoshi, Kazumasa Mogi, Emiri Miyamoto, Sae Hayakawa, Maia Hayashi, Satoshi Nomura, Kazuhisa Kitami, Kaname Uno, Mai Sugiyama, Yoshihiro Koya, Yoshihiko Yamakita, Akihiro Nawa, Atsushi Enomoto, Carmela Ricciardelli, Hiroaki Kajiyama","doi":"10.1007/s10555-024-10169-8","DOIUrl":"10.1007/s10555-024-10169-8","url":null,"abstract":"Epithelial ovarian cancer (EOC) is often diagnosed in advanced stage with peritoneal dissemination. Recent studies indicate that aberrant accumulation of collagen fibers in tumor stroma has a variety of effects on tumor progression. We refer to remodeled fibrous stroma with altered expression of collagen molecules, increased stiffness, and highly oriented collagen fibers as tumor-associated fibrosis (TAF). TAF contributes to EOC cell invasion and metastasis in the intraperitoneal cavity. However, an understanding of molecular events involved is only just beginning to emerge. Further development in this field will lead to new strategies to treat EOC. In this review, we focus on the recent findings on how the TAF contributes to EOC malignancy. Furthermore, we will review the recent initiatives and future therapeutic strategies for targeting TAF in EOC.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":null,"pages":null},"PeriodicalIF":7.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140317785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic importance and diagnostic function of circRNAs in urological cancers: from metastasis to drug resistance. circRNA 在泌尿系统癌症中的治疗重要性和诊断功能：从转移到耐药性。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-09-01 Epub Date: 2024-01-22 DOI: 10.1007/s10555-023-10152-9

Zhibin Zhang, Zhixu Gao, Huimin Fang, Yutang Zhao, Rong Xing

{"title":"Therapeutic importance and diagnostic function of circRNAs in urological cancers: from metastasis to drug resistance.","authors":"Zhibin Zhang, Zhixu Gao, Huimin Fang, Yutang Zhao, Rong Xing","doi":"10.1007/s10555-023-10152-9","DOIUrl":"10.1007/s10555-023-10152-9","url":null,"abstract":"Circular RNAs (circRNAs) are a member of non-coding RNAs with no ability in encoding proteins and their aberrant dysregulation is observed in cancers. Their closed-loop structure has increased their stability, and they are reliable biomarkers for cancer diagnosis. Urological cancers have been responsible for high mortality and morbidity worldwide, and developing new strategies in their treatment, especially based on gene therapy, is of importance since these malignant diseases do not respond to conventional therapies. In the current review, three important aims are followed. At the first step, the role of circRNAs in increasing or decreasing the progression of urological cancers is discussed, and the double-edged sword function of them is also highlighted. At the second step, the interaction of circRNAs with molecular targets responsible for urological cancer progression is discussed, and their impact on molecular processes such as apoptosis, autophagy, EMT, and MMPs is highlighted. Finally, the use of circRNAs as biomarkers in the diagnosis and prognosis of urological cancer patients is discussed to translate current findings in the clinic for better treatment of patients. Furthermore, since circRNAs can be transferred to tumor via exosomes and the interactions in tumor microenvironment provided by exosomes such as between macrophages and cancer cells is of importance in cancer progression, a separate section has been devoted to the role of exosomal circRNAs in urological tumors.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":null,"pages":null},"PeriodicalIF":7.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139511868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glioblastoma stem cell metabolism and immunity. 胶质母细胞瘤干细胞的新陈代谢与免疫。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-09-01 Epub Date: 2024-03-26 DOI: 10.1007/s10555-024-10183-w

Joseph Hawly, Micaela G Murcar, Alejandro Schcolnik-Cabrera, Mark E Issa

引用次数: 0

Survival mechanisms of circulating tumor cells and their implications for cancer treatment. 循环肿瘤细胞的生存机制及其对癌症治疗的影响。

IF 7.7 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-09-01 Epub Date: 2024-03-04 DOI: 10.1007/s10555-024-10178-7

Shuang Zhou, Huanji Xu, Yichun Duan, Qiulin Tang, Huixi Huang, Feng Bi

引用次数: 0

Regulation and targeting of SREBP-1 in hepatocellular carcinoma. SREBP-1在肝细胞癌中的调控和靶向作用。

IF 9.2 2区医学

Cancer and Metastasis Reviews Pub Date : 2024-06-01 Epub Date: 2023-12-01 DOI: 10.1007/s10555-023-10156-5

Fengting Su, Andreas Koeberle

{"title":"Regulation and targeting of SREBP-1 in hepatocellular carcinoma.","authors":"Fengting Su, Andreas Koeberle","doi":"10.1007/s10555-023-10156-5","DOIUrl":"10.1007/s10555-023-10156-5","url":null,"abstract":"Hepatocellular carcinoma (HCC) is an increasing burden on global public health and is associated with enhanced lipogenesis, fatty acid uptake, and lipid metabolic reprogramming. De novo lipogenesis is under the control of the transcription factor sterol regulatory element-binding protein 1 (SREBP-1) and essentially contributes to HCC progression. Here, we summarize the current knowledge on the regulation of SREBP-1 isoforms in HCC based on cellular, animal, and clinical data. Specifically, we (i) address the overarching mechanisms for regulating SREBP-1 transcription, proteolytic processing, nuclear stability, and transactivation and (ii) critically discuss their impact on HCC, taking into account (iii) insights from pharmacological approaches. Emphasis is placed on cross-talk with the phosphatidylinositol-3-kinase (PI3K)-protein kinase B (Akt)-mechanistic target of rapamycin (mTOR) axis, AMP-activated protein kinase (AMPK), protein kinase A (PKA), and other kinases that directly phosphorylate SREBP-1; transcription factors, such as liver X receptor (LXR), peroxisome proliferator-activated receptors (PPARs), proliferator-activated receptor γ co-activator 1 (PGC-1), signal transducers and activators of transcription (STATs), and Myc; epigenetic mechanisms; post-translational modifications of SREBP-1; and SREBP-1-regulatory metabolites such as oxysterols and polyunsaturated fatty acids. By carefully scrutinizing the role of SREBP-1 in HCC development, progression, metastasis, and therapy resistance, we shed light on the potential of SREBP-1-targeting strategies in HCC prevention and treatment.","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":null,"pages":null},"PeriodicalIF":9.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11156753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138458070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0